Allogeneic Stem Cell Transplantation Market Analysis and Forecast to 2032:By Source of Stem Cells (Bone Marrow Transplantation (BMT), Peripheral Blood Stem Cell Transplantation (PBSCT), Cord Blood Transplantation (CBT)), Donor Types (Related Donor Transplants, Unrelated Donor Transplants), Condition Treated (Hematologic Malignancies, Non-Malignant Disorders), and Region

Allogeneic stem cell transplantation is a type of stem cell therapy used to treat various types of cancers and some other diseases. It is a procedure in which healthy stem cells from a donor are transplanted into a patient’s body to replace damaged or diseased cells. The donor stem cells are usually a close relative of the patient, such as a brother or sister, but can also be an unrelated donor.

Allogeneic stem cell transplantation is used to treat a variety of cancers and some other diseases. It can be used to replace diseased bone marrow or to treat some forms of leukemia, lymphoma, and multiple myeloma. It can also be used to treat certain inherited blood disorders, such as sickle cell anemia and thalassemia. In some cases, allogeneic stem cell transplantation is the only available treatment option for certain diseases.

Allogeneic stem cell transplantation is a complex procedure that requires a great deal of preparation. Before the transplant, the patient must undergo extensive testing to ensure that the donor’s stem cells are a good match for the patient. The patient also needs to receive chemotherapy and/or radiation therapy to prepare the body for the transplant. During the procedure, the donor stem cells are infused into the patient’s bloodstream via a vein. The stem cells migrate to the bone marrow, where they start producing new, healthy blood cells.

The risks of allogeneic stem cell transplantation include infection, organ damage, and graft-versus-host disease (GVHD). GVHD occurs when the donor cells attack the patient’s healthy cells. GVHD can be mild, moderate, or severe, depending on the patient’s age, the type of transplant, and other factors.

Allogeneic stem cell transplantation is a potentially life-saving treatment for many patients with certain cancers and other diseases. The procedure is complex and carries risks, but it can offer a chance for a cure or a significant improvement in quality of life.

Key Trends

Allogeneic stem cell transplantation (ASCT) is a medical procedure that involves the transplantation of stem cells from one person (the donor) to another (the recipient). The stem cells are taken from the donor’s bone marrow or peripheral blood, and used to replace the recipient’s damaged or abnormal stem cells. ASCT is a treatment option for a variety of conditions, such as certain types of cancer, blood disorders, and immune system deficiencies.

In recent years, the field of allogeneic stem cell transplantation has seen a number of advances and breakthroughs. These advances have made ASCT a more effective and less risky procedure, as well as opened up a range of new therapeutic possibilities. Here are some of the key trends in allogeneic stem cell transplantation technology.

1. Reduced Graft-versus-Host Disease (GvHD): GvHD is a common complication of allogeneic stem cell transplants, and can cause serious health problems for the recipient. Recent advances in stem cell transplantation technology have led to the development of new techniques, such as the use of T-cell depleted grafts, which reduce the risk of GvHD.

2. Improved Engraftment Rates: Engraftment is the process by which donor stem cells become established in the recipient’s body. Improved engraftment rates are essential for successful stem cell transplants, as it ensures that the transplanted cells are able to repopulate the recipient’s bone marrow. Recent advances in stem cell transplantation technology have led to improved engraftment rates, making ASCT a more successful procedure.

3. Reduced Risk of Infection: Infection is a major risk associated with allogeneic stem cell transplants, as the recipient’s immune system is weakened during the procedure. However, advances in stem cell transplantation technology, such as the use of T-cell depleted grafts, have led to a reduced risk of infection.

Key Drivers

Allogeneic stem cell transplantation is a medical procedure that involves the transplantation of stem cells from a donor to a recipient. It is used to treat a range of conditions, including cancer, blood disorders, and immune system deficiencies. Allogeneic stem cell transplants are an important part of the field of regenerative medicine, as they have the potential to replace damaged or diseased cells with healthy ones from a donor.

The key drivers of the Allogeneic Stem Cell Transplantation market are as follows:

1. Increasing Incidence of Blood Cancers and Other Disorders: The increasing incidence of blood cancers and other hematological disorders, such as leukemia, myeloma, and lymphoma, is driving the demand for allogeneic stem cell transplants. According to the Leukemia & Lymphoma Society, approximately 173,000 new cases of leukemia are diagnosed each year in the United States. The rising prevalence of blood disorders is leading to an increased demand for stem cell transplants, thus driving the market.

2. Technological Advancements: Technological advancements in the field of stem cell transplantation are driving the market. The development of new and improved stem cell transplantation techniques, such as cord blood transplantation, haploidentical stem cell transplantation, and gene therapy, have made the procedure more effective and safer. These advancements have also made it possible to treat more complex diseases and conditions.

3. Growing Awareness: Growing awareness about the benefits of stem cell transplants is driving the market. There is an increasing number of people who are aware of the advantages of stem cell transplants and the potential for curing diseases and conditions, such as cancer and blood disorders. This is leading to an increased demand for the procedure, thus driving the market.

Restraints & Challenges

Allogeneic stem cell transplantation (alloSCT) is a promising treatment option for a variety of blood-related and/or immunological disorders, but it is associated with a number of risks and challenges. The major restraints and challenges in allogeneic stem cell transplantation are discussed below.

Immunological Rejection: Immunological rejection is one of the major challenges of allogeneic stem cell transplantation. During allogeneic stem cell transplantation, the donor’s immune system may recognize the recipient’s cells as foreign and attack them. This can lead to graft-versus-host disease (GVHD), a potentially fatal complication. To reduce the risk of GVHD, immunosuppressant drugs are often given to the patient. However, these drugs can also weaken the patient’s immune system, making them more prone to infection.

Graft Failure: Graft failure is another major challenge of allogeneic stem cell transplantation. Graft failure occurs when the donor’s cells do not engraft or take hold in the patient’s body, or when the engrafted cells are destroyed by the patient’s immune system. This can lead to a number of serious complications, including organ damage, infection, and death.

Infection: Infection is a major risk for patients undergoing allogeneic stem cell transplantation. Immunosuppressant drugs can weaken the patient’s immune system, making them more susceptible to infection. In addition, the procedure itself can increase the risk of infection, as it involves introducing new cells into the body.

Cost: Allogeneic stem cell transplantation is a costly and complex procedure.

Market Segments

The global  Allogeneic Stem Cell Transplantation Market is segmented by source of stem cells, donor types, condition treated, and region. By source of stem cells, the market is divided into bone marrow transplantation (BMT), peripheral blood stem cell transplantation (PBSCT), and cord blood transplantation (CBT). Based on donor types, it is bifurcated into related donor transplants, and unrelated donor transplants. On the basis of condition treated, the market is classified into hematologic malignancies, and non-malignant disorders. Region-wise, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

Key Players

The global  Allogeneic Stem Cell Transplantation Market report includes players like Gilead Sciences (USA) , Novartis AG (Switzerland) , Fresenius SE & Co. KGaA (Germany) , Regeneron Pharmaceuticals (USA), Pluristem Therapeutics Inc. (Israel) , Mesoblast Limited (Australia) , Kiadis Pharma (Netherlands) , Gamida Cell Ltd. (Israel) , Takeda Pharmaceutical Company Limited (Japan) , Cynata Therapeutics Limited (Australia)

 Allogeneic Stem Cell Transplantation Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current  Allogeneic Stem Cell Transplantation Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of  Allogeneic Stem Cell Transplantation Market in terms of revenue ($Million).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the  Allogeneic Stem Cell Transplantation Market .
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country market analysis is also presented in this report.
  • Analytical depiction of the  Allogeneic Stem Cell Transplantation Market along with the current trends and future estimations to depict imminent investment pockets. The overall  Allogeneic Stem Cell Transplantation Market opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the  Allogeneic Stem Cell Transplantation Market are also analyzed.

Why GIS?

 

Table of Contents

Chapter 1. Allogeneic Stem Cell Transplantation Market Overview
1.1. Objectives of the Study
1.2. Market Definition and Research & Scope
1.3. Research Limitations
1.4. Years & Currency Considered in the Study
1.5. Research Methodologies
1.5.1. Secondary Research
1.5.1.1. Data Collection
1.5.1.2. List of Secondary Sources
1.5.1.3. Key Data from Secondary Sources
1.5.2. Primary Research
1.5.2.1. List of Primary Research Sources
1.5.3. Market Flavor Estimation: Top-Down Approach
1.5.4. Market Flavor Estimation: Bottom-Up Approach
1.5.5. Data Triangulation and Validation

Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of the Market
2.3. Analyst’s Review

Chapter 3. Premium Insights on the Market
3.1. Market Attractiveness Analysis, by Region
3.2. Market Attractiveness Analysis, by Source of Stem Cells
3.3. Market Attractiveness Analysis, by Donor Types
3.4. Market Attractiveness Analysis, by Condition Treated

Chapter 4. Allogeneic Stem Cell Transplantation Market Outlook
4.1. Allogeneic Stem Cell Transplantation Market Segmentation
4.2. Market Dynamics
4.2.1. Market Drivers
4.2.1.1. Driver 1
4.2.1.2. Driver 2
4.2.1.3. Driver 3
4.2.2. Market Restraints
4.2.2.1. Restraint 1
4.2.2.2. Restraint 2
4.2.3. Market Opportunities
4.2.3.1. Opportunity 1
4.2.3.2. Opportunity 2
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Buyers
4.3.4. Bargaining Power of Supplier
4.3.5. Competitive Rivalry
4.4. PESTLE Analysis
4.5. Value Chain Analysis
4.5.1. Raw Material Suppliers
4.5.2. Manufacturers
4.5.3. Wholesalers and/or Retailers
4.6. Impact of COVID-19 on the Allogeneic Stem Cell Transplantation Market
4.7. Impact of the Russia and Ukraine War on the Allogeneic Stem Cell Transplantation Market
4.8. Case Study Analysis
4.9. Pricing Analysis

Chapter 5. Allogeneic Stem Cell Transplantation Market , by Source of Stem Cells
5.1. Market Overview
5.2. Bone Marrow Transplantation (BMT)
5.2.1. Key Market Trends & Opportunity Analysis
5.2.2. Market Size and Forecast, by Region
5.3. Peripheral Blood Stem Cell Transplantation (PBSCT)
5.3.1. Key Market Trends & Opportunity Analysis
5.3.2. Market Size and Forecast, by Region
5.4. Cord Blood Transplantation (CBT)
5.4.1. Key Market Trends & Opportunity Analysis
5.4.2. Market Size and Forecast, by Region

Chapter 6. Allogeneic Stem Cell Transplantation Market , by Donor Types
6.1. Market Overview
6.2. Related Donor Transplants
6.2.1. Key Market Trends & Opportunity Analysis
6.2.2. Market Size and Forecast, by Region
6.3. Unrelated Donor Transplants
6.3.1. Key Market Trends & Opportunity Analysis
6.3.2. Market Size and Forecast, by Region
Chapter 7. Condition Treated
7.1. Market Overview
7.2. Hematologic Malignancies
7.2.1. Key Market Trends & Opportunity Analysis
7.2.2. Market Size and Forecast, by Region
7.3. Non-Malignant Disorders
7.3.1. Key Market Trends & Opportunity Analysis
7.3.2. Market Size and Forecast, by Region

Chapter 8. Allogeneic Stem Cell Transplantation Market , by Region
8.1. Overview
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. North America Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.2.3. North America Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.2.4. North America Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.2.5. North America Allogeneic Stem Cell Transplantation Market Size and Forecast, by Country
8.2.6. The U.S.
8.2.6.1. The U.S. Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.2.6.2. The U.S. Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.2.6.3. The U.S. Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.2.7. Canada
8.2.7.1. Canada Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.2.7.2. Canada Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.2.7.3. Canada Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.2.8. Mexico
8.2.8.1. Mexico Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.2.8.2. Mexico Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.2.8.3. Mexico Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Europe Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.3. Europe Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.4. Europe Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.5. Europe Allogeneic Stem Cell Transplantation Market Size and Forecast, by Country
8.3.6. The U.K.
8.3.6.1. The U.K. Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.6.2. The U.K. Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.6.3. The U.K. Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.7. Germany
8.3.7.1. Germany Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.7.2. Germany Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.7.3. Germany Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.8. France
8.3.8.1. France Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.8.2. France Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.8.3. France Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.9. Spain
8.3.9.1. Spain Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.9.2. Spain Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.9.3. Spain Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.10. Italy
8.3.10.1. Italy Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.10.2. Italy Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.10.3. Italy Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.11. Netherlands
8.3.11.1. Netherlands Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.11.2. Netherlands Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.11.3. Netherlands Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.12. Sweden
8.3.12.1. Sweden Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.12.2. Sweden Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.12.3. Sweden Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.13. Switzerland
8.3.13.1. Switzerland Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.13.2. Switzerland Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.13.3. Switzerland Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.14. Denmark
8.3.14.1. Denmark Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.14.2. Denmark Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.14.3. Denmark Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.15. Finland
8.3.15.1. Finland Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.15.2. Finland Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.15.3. Finland Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.16. Russia
8.3.16.1. Russia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.16.2. Russia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.16.3. Russia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.3.17. Rest of Europe
8.3.17.1. Rest of Europe Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.3.17.2. Rest of Europe Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.3.17.3. Rest of Europe Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Asia-Pacific Allogeneic Stem Cell Transplantation Market Size and Forecast, by Country
8.4.3. Asia-Pacific Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.4. Asia-Pacific Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.5. Asia-Pacific Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.6. China
8.4.6.1. China Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.6.2. China Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.6.3. China Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.7. India
8.4.7.1. India Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.7.2. India Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.7.3. India Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.8. Japan
8.4.8.1. Japan Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.8.2. Japan Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.8.3. Japan Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.9. South Korea
8.4.9.1. South Korea Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.9.2. South Korea Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.9.3. South Korea Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.10. Australia
8.4.10.1. Australia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.10.2. Australia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.10.3. Australia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.11. Singapore
8.4.11.1. Singapore Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.11.2. Singapore Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.11.3. Singapore Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.12. Indonesia
8.4.12.1. Indonesia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.12.2. Indonesia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.12.3. Indonesia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.13. Taiwan
8.4.13.1. Taiwan Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.13.2. Taiwan Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.13.3. Taiwan Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.14. Malaysia
8.4.14.1. Malaysia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.14.2. Malaysia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.14.3. Malaysia Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.4.15. Rest of APAC
8.4.15.1. Rest of APAC Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.4.15.2. Rest of APAC Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.4.15.3. Rest of APAC Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.5. Rest of The World
8.5.1. Key Market Trends and Opportunities
8.5.2. Rest of The World Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.5.3. Rest of The World Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.5.4. Rest of The World Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.5.5. Rest of The World Allogeneic Stem Cell Transplantation Market Size and Forecast, by Country
8.5.6. Latin America
8.5.6.1. Latin America Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.5.6.2. Latin America Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.5.6.3. Latin America Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.5.7. Middle East
8.5.7.1. Middle East Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.5.7.2. Middle East Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.5.7.3. Middle East Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types
8.5.8. Africa
8.5.8.1. Africa Allogeneic Stem Cell Transplantation Market Size and Forecast, by Source of Stem Cells
8.5.8.2. Africa Allogeneic Stem Cell Transplantation Market Size and Forecast, by Condition Treated
8.5.8.3. Africa Allogeneic Stem Cell Transplantation Market Size and Forecast, by Donor Types

Chapter 9. Competitive Landscape
9.1. Market Overview
9.2. Market Share Analysis/Key Player Positioning
9.3. Competitive Leadership Mapping
9.3.1. Star Players
9.3.2. Innovators
9.3.3. Emerging Players
9.4. Vendor Benchmarking
9.5. Developmental Strategy Benchmarking
9.5.1. New Product Developments
9.5.2. Product Launches
9.5.3. Business Expansions
9.5.4. Partnerships, Joint Ventures, and Collaborations
9.5.5. Mergers and Acquisitions

Chapter 10. Company Profiles
10.1. Gilead Sciences (USA)
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Product Offerings
10.1.4. Key Strategic Initiatives
10.1.5. SWOT Analysis
10.2. Novartis AG (Switzerland)
10.2.1. Company Snapshot
10.2.2. Financial Performance
10.2.3. Product Offerings
10.2.4. Key Strategic Initiatives
10.2.5. SWOT Analysis
10.3. Fresenius SE & Co. KGaA (Germany)
10.3.1. Company Snapshot
10.3.2. Financial Performance
10.3.3. Product Offerings
10.3.4. Key Strategic Initiatives
10.3.5. SWOT Analysis
10.4. Regeneron Pharmaceuticals (USA)
10.4.1. Company Snapshot
10.4.2. Financial Performance
10.4.3. Product Offerings
10.4.4. Key Strategic Initiatives
10.4.5. SWOT Analysis
10.5. Pluristem Therapeutics Inc. (Israel)
10.5.1. Company Snapshot
10.5.2. Financial Performance
10.5.3. Product Offerings
10.5.4. Key Strategic Initiatives
10.5.5. SWOT Analysis
10.6. Mesoblast Limited (Australia)
10.6.1. Company Snapshot
10.6.2. Financial Performance
10.6.3. Product Offerings
10.6.4. Key Strategic Initiatives
10.6.5. SWOT Analysis
10.7. Gamida Cell Ltd. (Israel)
10.7.1. Company Snapshot
10.7.2. Financial Performance
10.7.3. Product Offerings
10.7.4. Key Strategic Initiatives
10.7.5. SWOT Analysis
10.8. Takeda Pharmaceutical Company Limited (Japan)
10.8.1. Company Snapshot
10.8.2. Financial Performance
10.8.3. Product Offerings
10.8.4. Key Strategic Initiatives
10.8.5. SWOT Analysis
10.9. Cynata Therapeutics Limited (Australia)
10.9.1. Company Snapshot
10.9.2. Financial Performance
10.9.3. Product Offerings
10.9.4. Key Strategic Initiatives
10.9.5. SWOT Analysis
10.10. Kiadis Pharma (Netherlands)
10.10.1. Company Snapshot
10.10.2. Financial Performance
10.10.3. Product Offerings
10.10.4. Key Strategic Initiatives
10.10.5. SWOT Analysis

*The List of Company Is Subject To Change During The Final Compilation of The Report
Market Segments

By Source of Stem Cells

  • Bone Marrow Transplantation (BMT)
  • Peripheral Blood Stem Cell Transplantation (PBSCT)
  • Cord Blood Transplantation (CBT)

By Donor Types

  • Related Donor Transplants
  • Unrelated Donor Transplants

By Condition Treated

  • Hematologic Malignancies
  • Non-Malignant Disorders

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

The global small intestinal bacterial overgrowth diagnostics market…
Bioinformatics is the application of computer science and…
Spinal stenosis is a condition that occurs when…
The Marine Collagen market size was USD 839.3…
Immunofluorescence assay (IFA) is an analytical technique used…
Myasthenia gravis is a chronic autoimmune neuromuscular condition…
Graft Versus Host disease (GVHD) is an immune…
Antibody Drug Conjugates (ADC's) are biopharmaceutical drugs used…
Tissue engineering is a branch of regenerative medicine…
Muscle relaxant drugs are medications that are used…